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A B S T R A C T   
Drug delivery to the brain is limited for most pharmaceuticals by the blood-brain barrier (BBB) where claudin-5 
dominates the paraendothelial tightening. For circumventing the BBB, we identified the compound M01 as a 
claudin-5 interaction inhibitor. M01 causes transient permeabilisation of the BBB depending on the concentra-
tion of small molecules in different cell culture models within 3 to 48 h. In mice, brain uptake of fluorescein 
peaked within the first 3 h after M01 injection and normalised within 48 h. Compared to the cytostatic paclitaxel 
alone, M01 improved delivery of paclitaxel to mouse brain and reduced orthotopic glioblastoma growth. Results 
on interactions of M01 with claudin-5 were incorporated into a binding model which suggests association of its 
aromatic parts with highly conserved residues of the extracellular domain of claudin-5 and adjacent trans-
membrane segments. Our results indicate the following mode of action: M01 preferentially binds to the extra-
cellular claudin-5 domain, which weakens trans-interactions between adhering cells. Further decrease in 
membranous claudin-5 levels due to internalization and transcriptional downregulation enables the paracellular 
passage of small molecules. In summary, the first small molecule is introduced here as a drug enhancer, which 
specifically permeabilises the BBB for a sufficient interval for allowing neuropharmaceuticals to enter the brain.   
1. Introduction 
Tight junctions (TJs) are one of the main restrictors for the perme-
ability of solutes across epithelial and endothelial cell barriers. They 
consist of transmembrane proteins, in particular claudins [1] and TJ- 
associated MARVEL proteins, such as occludin [2]. In addition, cyto-
solic TJ-plaque proteins (e.g., Zonula occludens protein-1, ZO-1) are 
associated with the TJs. Within TJs, claudins have a superior role in 
sealing the paracellular space against water soluble molecules and ions 
[3]. Tissue compartmentation and homeostasis is thus a consequence of 
the spatial restriction. However, the tightening activity of the 25 
members of the claudin family [1,4] differs considerably, and perme-
ability properties of a cell layer are largely determined by the tissue- 
specific claudin expression pattern [1]. 
The blood-brain barrier (BBB) is one of the most restrictive cell 
barriers. Brain capillary endothelial cells form the BBB under the in-
fluence of surrounding structures and constitute a prerequisite for the 
homeostasis of the central nervous system. In these endothelial cells, the 
paracellularly tightening claudin-5 is the functionally dominating 
claudin [5,6]. The deficiency of claudin-5 is lethal for new-born mice 
[7]. Knockout and siRNA revealed that loss of claudin-5 from brain 
microvascular endothelial cells leads to a size-selective BBB opening for 
molecules ≤800 Da [7,8] - the molecular range of 98% of all pharma-
ceuticals [9,10]. While protecting the brain against harmful substances, 
the claudin-5-mediated BBB tightening is a major obstacle for the par-
aendothelial delivery of hydrophilic drugs [11]. 
Claudins are composed of four transmembrane helices [12], an 
extracellular oligomerisation domain [12,13], intracellular loop, cyto-
solic N- and C-terminus [3]. Their paracellular tightening function is 
mediated by the extracellular domain [14,15] via direct intercellular 
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association between claudins from adjacent cells, called trans-interac-
tion [16]. Consequently, targeting claudin-5 oligomerisation is a 
promising strategy for a specific and size-selective permeabilisation of 
the BBB to increase the uptake of small hydrophilic drugs to the brain. 
Procedures to permeabilise the BBB, which are in clinical use 
(hyperosmolar mannitol) or in clinical testing (e.g., ultrasound, nano-
particles), are not target-oriented. Moreover, the latter are accompanied 
by serious side-effects, problems with dosing or with reproducibility 
[17]. Several other small molecules, such as Labradimal (also referred to 
as RMP-7 or Cereport®), AT1001 (synonym: larazotide acetate) or 
PN159 have been tested for their ability of transient opening of the BBB. 
Despite encouraging results in cellular and animal models, their clinical 
use as permeation enhancers has been abandoned [18]. This also refers 
to the application of short chain alkylglycerols for BBB opening [19]. 
Nanomedical approaches raised great expectations with respect to their 
use as permeability enhancers; several types of nanoparticles providing 
BBB drug transport have been or are currently being investigated in 
clinical trials for their efficacy in brain tumour treatment, in particular 
glioblastoma multiforme [20]. Specific peptidomimetics derived from 
claudins expressed at the BBB are target-oriented [21,22]. It has been 
shown that treatment with synthetic peptides from the extracellular 
domain of claudin-5 permeabilises cell culture models of the BBB as well 
as the murine BBB in vivo and improves the permeability of cytostatics 
such as doxorubicin [22]. However, proper generation and handling of 
peptide drugs is expensive, and degradation and rapid elimination limit 
the bioavailability of short-chain peptides. 
Consequently, the aim of this study was to identify agents that fulfil 
the prerequisites for the development of pharmaceuticals [9,23]. 
Candidate molecules were characterized as preferentially associating to 
claudin-5 and were proven to permeabilise the BBB transiently and 
moderately to avoid side effects. This approach was successfully 
exploited for improved delivery of cytostatics to reduce brain tumour 
growth. 
2. Material and methods 
2.1. Drug enhancers 
Drug enhancers investigated to modulate claudin-5 tissue barriers 
are depicted in Fig. 1A. M01 and derivatives were purchased from SIA 
Enamine Riga, Latvia, for substance screening experiments, cell culture 
experiments with Madin-Darby canine kidney (MDCK-II) or human 
embryonic kidney (HEK)-293 cells, and all experiments with M01A and 
–B. Experiments with bEnd.3 and all animal experiments were per-
formed with M01, 2-[5-(p-Methoxyphenyl)-3-phenyl-4,5-dihydro-1H- 
pyrazol-1-yl]-2-oxoethyl 1-ethyl-7-methyl-4-oxo-1,8-diaza-3-naph-
thoate], synthesized by ASCA GmbH (Berlin, Germany). Properties of 
M01 (C30H28N4O5) are given Fig. 1A. The purity, proven by mass 
spectrometry, was >95%. 
Fig. 1. M01, a small molecule affecting the tight 
junction protein claudin-5. M01 was identified in a 
screening approach (supplementary Materials and 
Methods). A) Structure and physicochemical proper-
ties of M01 and its derivatives M01A and M01B. B) 
Yellow fluorescence protein (YFP)-Cldn5 but not YFP 
expressing human embryonic kidney (HEK-293) cells 
showed reduced YFP-fluorescence after overnight 
treatment with 20 μM M01 in live cell imaging. Scale 
bar, 10 μm. The fluorescence intensity was quantified 
and normalised to DMSO treated control conditions 
(bar chart, bottom). Data presented as mean ± SEM, 
n ≥ 16 images, Kruskal-Wallis-test followed by 
Dunn’s multiple comparison test. ***, p < 0.001. (For 
interpretation of the references to colour in this 
figure legend, the reader is referred to the web 
version of this article.)   
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2.2. Cell culture 
HEK-293 (passage 22) and MDCK-II cells (passage 34) were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM; Life Technolo-
gies, Darmstadt, Germany), including 10% foetal calf serum (FCS; Life 
Technologies), 100 units/ml penicillin, 100 mg/ml streptomycin (Bio-
chrom, Berlin, Germany) at 37 ◦C and 10% CO2 [21]. The murine brain 
endothelial cell line bEND.3 [22] (a gift of Anuska Andjelkovic, Uni-
versity of Michigan; passages 20–28) was cultivated under the same 
conditions but with 4.5 g/l glucose DMEM (Thermo Fisher Scientific, 
Darmstadt, Germany). HEK-293 (ACC 305) and MDCK-II cells (ACC 169) 
were obtained from the German Collection of Microorganisms and Cell 
Cultures GmbH (Braunschweig, Germany). All claudin-transfected cells 
were used as stably expressing cell lines (HEK-293: EYFP-cldn-1, − 3, 
− 4, − 5, YFPSTOP, and cldn-1-, cldn-2-, cldn-3-, cldn-4- and cldn-5-EYFP; 
MDCK-II: flag-cldn-5). Plasmids are listed in Supplementary Table 1. 
Stable cell lines were generated by transfection of 90% confluent cells on 
poly-L-lysine hydrobromide (20 μg/ml in Dulbecco’s phosphate buffered 
saline (DPBS; Sigma-Aldrich, Taufkirchen, Germany) coated 6-well 
plates (TPP, Trasadingen, Germany) with 2 μg plasmid DNA and 10 μl 
polyethyleneimine (PEI, #23966–1, Polyscience Europe GmbH, Eppel-
heim, Germany) mixed with 250 μl Opti-MEM (Biochrom). Next day, the 
transfection mix was exchanged against culture medium with 0.5 μg/ml 
geneticin (Biochrom). FACS (FACSaria, Becton Dickinson, Heidelberg, 
Germany) was performed to enrich YFP-expressing cells. Harvested 
claudin expressing cells were cultivated and aliquots frozen in liquid 
nitrogen until use. 
2.3. Cytotoxicity 
Confluent cells (48-well plates coated with rat-tail collagen, Roche 
Diagnostics, Mannheim, Germany) were incubated with test compounds 
in complete medium without phenol red for 16 h. Cells were washed, 
and 200 μl MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazoliumbromide; 0.5 g/ml, Sigma–Aldrich) was added to each well 
[22]. After 3 h, cells were washed and 200 μl of extraction solution per 
well was added (5% Triton X-100, 95% isopropanol). After 15 min 
vortexing (800 U/min), the signal intensity was determined (at 570 nm) 
using a plate reader (Safire, Tecan Infinite M1000 Pro; Tecan, Maen-
nedorf, Switzerland) to calculate cell viability. 
2.4. Microscale thermophoresis 
Lysates were obtained from nearly confluent stably transfected HEK- 
293 claudin-YFP [24] or YFP alone expressing cells as negative control: 
cells were washed (2× PBS), scraped off, and centrifuged (10 min, 250 
×g). Pellets were resuspended in lysis buffer (20 mM Tris/HCl, pH 7.5, 
100 mM NaCl, 1 mM MgCl2, 5% glycerol, 5 units benzonase containing 
protease inhibitors (Roche)), pressed 5× through a 25-G needle, and 
centrifuged (10 min, 10,000 ×g, 4 ◦C) [25]. M01 was added in a defined 
amount as titration series (15 dilutions) in PBS to cell lysates containing 
fluorescently labelled claudins 1 to 5. After incubation (1 h, 22 ◦C), 
samples were loaded into standard treated capillaries, and the fluores-
cence was measured with Monolith NT.115 (light-emitting diode power 
50%, infrared laser power 80%, and laser on time 35 s). The evaluation 
was performed with NT Analysis software 1.2.229 (NanoTemper, 
Munich, Germany), and binding was characterized by the dissociation 
constant (Kd). Determination was accomplished using saturation curves 
obtained at equilibrium conditions. 
2.5. Transcellular electrical resistance (TER), impedance and permeation 
measurements 
Resistance of bEND.3 cell monolayers seeded in 8-well electrode 
arrays (Electric Cell-Substrate Impedance System; model 1600R, 
Applied Biophysics, Troy, NY) were measured at 4 kHz and used to 
evaluate the impedance. At plateau values, cells were treated with the 
compounds tested. MDCK-II or MDCK-II-flag-Cldn5 were grown on rat- 
tail collagen–coated transwell filter inserts (10 mm diameter, 0.4 μm 
pore size, Millicell-CM; Millipore, Eschborn, Germany). TER was 
measured with an EVOM voltohmmeter (WPI, Sarasota, USA) and 
calculated in Ω ⋅ cm2. Permeation was determined using 457-Da lucifer 
yellow (LY, Sigma–Aldrich) that was added luminally. LY (0.05 mg/ml) 
was dissolved in permeation buffer: Hank’s buffered salt solution Ca2+/ 
Mg2+ (HBSS+/+, Thermo Fisher), 5% FCS, and 10 mM HEPES (4-(2- 
hydroxyethyl)-1-piperazineethanesulfonic acid; PAA Laboratories, 
Pasching, Austria). Fluorescence of LY was measured with a microplate 
reader (Tecan) and the apparent permeability coefficient (Papp) was 
calculated by the following equation: Papp = dQ/dt ⋅ (1/A ⋅ C0 ⋅ 60) in 
cm/s; dQ/dt is the permeability of the tracer (mg/min), A is the surface 
area of the filter (cm2), C0 is the concentration of the tracer in the apical 
compartment (mg/min) [21]. 
2.6. Quantitative real-time polymerase chain reaction (qRT-PCR) 
RNA was extracted using GeneMATRIX Universal RNA Purification 
Kit (EURx, Gdansk, Poland). The cDNA was synthesized with the Max-
ima First Strand cDNA Syntheses Kit (Thermo Fisher Scientific). qRT- 
PCR was performed with StepOnePlus RT-PCR system (48/96well, Life 
Technologies) using Luminaris Color HiGreen high ROX qPCRMas-
terMix (Thermo Fisher Scientific) according to the manufacturer’s rec-
ommendations. Primer pairs for qRT-PCR with approx. 20 bases and a 
melting temperature of about 60◦C [6] were designed using Primer3-
Plus.com [26] (Supplementary Table 2). For the comparison of the 
mRNA level of different genes, the detected cycle thresholds (Ct) were 
normalised to β-actin (Actb) expression by calculating ΔCt = (CtActb – 
CtGene of interest) with a detection limit of 10− 5. 
2.7. Immunocytochemistry 
MDCK-II (on coverslips coated with poly-L-lysine hydrobromide; 25 
μg/ml) and bEnd.3 cells (rat-tail collagen coating, Roche; 0.67 mg/ml in 
0.2% acetic acid) were fixed in ice-cold acetone (5 min), ethanol (1 min) 
and PBS (2 min). After blocking (2% bovine serum albumin, Roth, 
Karlsruhe, Germany, 0.05% Triton X-100 in PBS; 45 min), cells were 
incubated with primary antibodies at 4 ◦C overnight. Then, four wash 
steps (à 5 min, PBS) were followed by 1 h incubation with secondary 
antibodies, four washings (5 min, PBS), short immersion in dist. H2O, 
and embedding in Roti-mount FluorCare DAPI (Roth). Antibodies were 
from Thermo Fisher Scientific (claudin-5, ZO-1), from Cell Signalling 
Technologies, Leiden, Netherlands (non-phospho (S45) β-catenin, 
phospho (T24) FoxO1 (#9464)), from AbD Serotec, Puchheim, Germany 
(GAPDH), from Biozol, Eching, Germany (ZO-1), and from R&D Sys-
tems, Minneapolis, USA (VE-cadherin). For dilutions and host, please 
refer to Supplementary Table 3. Stably expressing HEK-293 YFP-Cldn or 
Cldn-YFP were analysed via live cell imaging. For live cell imaging, cell 
membranes were stained with a few drops of trypan blue solution (0.4%; 
Gibco). Fluorescence was measured by using a LSM 710 Confocal Mi-
croscope System with EC Plan Neofluar 40×/1.3 or Plan apo 63×/1.4 
oil-objectives and ZEN Image Browser Software (Zeiss, Jena, Germany). 
Fluorescence intensities were quantified by ImageJ (NIH, Bethesda, 
USA), setting defined lines around the plasma membranes [22]. For 
trans-interaction, the fluorescently labelled claudin peaks on the in-
tensity profiles along the line connecting the centres of two neigh-
bouring HEK-293 cells were used to identify claudin-enriched contacts 
between two claudin expressing cells. The contact enrichment (EF) was 
applied to investigate the effect of M01 on the cell-to-cell binding [27]. 
2.8. Immunoblotting 
bEnd.3 cells were washed (PBS), lysed in ice-cold buffer (100 mM 
NaCl, 20 mM Tris/HCl, 1 mM MgCl2, 0.1% Triton X-100, 5% glycerol, 
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benzonase 20 U/ml with protease inhibitor (Roche), pH 7.5), homoge-
nized with a 25-G needle and centrifuged (4 ◦C, 10 min, 12,000 ×g). The 
supernatant was dissolved in sample buffer (0.225 M Tris/HCl, 50% 
glycerol, 5% Na-dodecyl sulphate, 0.05% bromophenol blue, 0.25 M 
dithiothreitol, pH 6.8), heated at 95 ◦C for 5 min (claudins 55 ◦C, 15 
min), and loaded on a polyacrylamide gel. Gels were run at 120 V in 
running buffer (25 mM Tris/HCl, 192 mM glycine, 0.1% Na-dodecyl 
sulphate, pH 8.3) for about 90 min. After separation, proteins were 
transferred on a nitrocellulose membrane (Bio-Rad Laboratories, Mün-
chen, Germany) at 4 ◦C and 100 V for 1 h and tested for the respective 
antibodies (Supplementary Table 3) at 4 ◦C overnight. 
2.9. M01 solubilisation 
The solubility properties of M01 were determined spectrophoto-
metrically (Spectrophotometer J-720, Jasco, Japan). Absorption spectra 
of 30 μM M01 in 1% DMSO dissolved in HBSS, M01 in 20% 2-hydrox-
ypropyl-β-cyclodextrin (HPβCD) or HPβCD alone were taken in the 
wavelength range from 270 nm to 450 nm. 
2.10. Brain uptake studies, animal treatment, and glioma model 
For investigation of the BBB, adult C57BL/6N mice were kept in 
standard conditions according to German animal welfare law in Berlin 
(G0030/13, LaGeSo). 650 μM M01 in PBS with 1% DMSO, 20% (HPβCD, 
4.5 μl/g b.w.) were administered into the tail vein resulting in 65 μM 
blood concentration; the injection was repeated 18 and 21 h later. The 
fluorescein uptake experiment was performed 3, 6, 12, 24 or 48 h after 
the final M01 treatment. Na-fluorescein (2%, 376 Da, Sigma-Aldrich) 
was injected i.v. (4.5 μl/g b.w.) 15 min after M01, while the mice 
were anesthetized (0.18 mg/g b.w. ketamine; CP-Pharma, Burgdorf, 
Germany; 0.024 mg/g b.w. xylazine; Ceva Tiergesundheit, Düsseldorf, 
Germany; i.p.). A volume of 25 ml PBS containing 6250 IU sodium 
heparin (Ratiopharm, Ulm, Germany) was perfused (1.5 ml/min) 
through the left ventricle of the heart. To evaluate Na-fluorescein, 100 
mg tissue was homogenized in 250 μl PBS followed by precipitation with 
250 μl 60% trichloric acid (>2 h, 4 ◦C) and centrifugation (18,000 ×g, 
20 min 4 ◦C). The fluorescence (λex 485 nm/λem 520 nm) of the super-
natant was determined using a Tecan plate reader. Brain uptake was 
calculated as μg fluorescein/mg brain [22] and normalised to brain 
uptake after control treatment (PBS, 3 h). 
In concert, the triple administration of 2.9 μmol/kg M01 (and 5.8 
μmol/kg), a 20% and 40% HPβCD solution (600 and 1200 μmol/kg), and 
1% and 2% DMSO (1.2 and 2.4 mmol/kg) did not exert any toxic effects. 
The mice grew normally (Supplementary Fig. 1) and without alterations 
in their appearance and behaviour (for example: grooming, breathing 
rate, signs of pain, activity, ingestion) even after weekly repetition over 
four weeks. For the glioma model, 20,000 U-87 MG cells (glioblastoma/ 
astrocytoma grade IV, 44 y old male Caucasian [28]) were intracranially 
inoculated in immunodeficient NMRI-Foxn1 nu− /− mice. Five days after 
injection of the cells, the mice received the triple administration pro-
cedure with M01 in HPβCD or PBS. Three hours after the third M01 
injection, the mice were treated with 28 μmol/kg paclitaxel or PBS as 
control (8 mice per group). The mice were weighed daily. The treatment 
scheme was repeated once a week for 4 weeks in total. Afterwards, the 
mice were euthanized, and the brains harvested. For quantitative eval-
uation of U87-MG glioma growth, the entire tumour containing area was 
cryosectioned. Consecutive cryosections were fixed with methanol (10 
min, − 20 ◦C), washed with dist. H2O, incubated with cresyl violet 
(0.1%, 10 min), and shortly treated with dist. H2O followed by 0.1% 
HCl. After dehydration and embedding in Roti Histo Kit (Roth), for each 
animal the brain slice with the largest tumour area was used for quan-
tification (Sigma Scan Pro, Systat Software, San Jose, USA) [29]. For the 
determination of the compound and metabolite concentration in serum, 
blood samples were taken from the tail vein of mice at time points 0.083, 
0.25, 0.5, 1, 3, 7 h after tail vein injection of 1.5 mg/kg M01, M01B or 
HPβCD (n = 3). For the quantification of excreted compounds, mice 
were transferred in metabolic cages for 24 h after injection. Afterwards, 
concentrations in urine and faeces (n = 3) were determined by LC-MS 
(Pharmacelsus GmbH, Saarbrücken, Germany). 
2.11. Molecular modelling, docking, and statistics 
The interaction surface between M01 and murine claudin-5 was 
modelled using SwissDock [30] based on the structure prediction of the 
claudin which was performed using Iterative Threading ASSEmbly 
Refinement (I-TASSER) [31]. The modelling also considered the exper-
imental data. If not stated otherwise, data were analysed using the 
Kruskal-Wallis test (one-way ANOVA) followed by Dunn’s multiple 
comparison post-test. Statistics and graphs were generated using 
GraphPad Prism5. 
3. Results 
M01 (Fig. 1A) was identified in a screening approach searching for 
molecules reducing claudin-5 (Cldn5) expression and cell-cell contact 
enrichment. HEK-293 cells are free of endogenous claudin expression 
[32]. In YFP-Cldn5 or YFP expressing HEK-293 cells, incubation with 20 
μM M01 overnight reduced the fluorescence intensity of YFP-Cldn5 
significantly but not the intensity of YFP (Fig. 1B). 
Next, we determined the effect of M01 on the homophilic claudin-5/ 
claudin-5 trans-association as detected by contact enrichment of 
claudin-5 between HEK-293 cells transfected with YFP-tagged claudin- 
5. Fig. 2A demonstrates that the fluorescence intensity of claudin-5 in 
cell contacts decreased with increased M01 concentrations. The effect 
was reversible as the fluorescence at the contacts recovered within 48 h 
(image Fig. 2A, bottom right). A reduction in junctional enrichment 
occurred within the first 3 h after incubation and became evident after 
17 h if more than 10 μM M01 were applied (Fig. 2A, B). After 48 h with 
M01 treatment, the junctional enrichment of claudin-5 was not different 
from the claudin-5 enrichment of the control treatment. However, 
merely a slight effect on TJ-like strands was observed after 17 h in freeze 
fracture electron microscopy (Supplementary Fig. 4). The effect of M01 
was mostly directed towards claudin-5 as demonstrated for HEK-293 
cells transfected with TJ forming BBB claudins-1 (compared to DMSO 
control, EF: 99.1% ± 9.05%), − 3 (EF: 95.2% ± 21.8%) and − 4 (EF: 
102.0% ±10.4%; Fig. 2C). Using microscale thermophoresis, the pref-
erential interaction of M01 with full-length claudin-5 (Kd: 237.7 ± 31.7 
nM) in cell extracts was quantified. In addition, a lower affinity to 
claudin-3 (Kd: 935.1 ± 199.6 nM) was found while dissociation con-
stants for other claudins were more than one order of magnitude lower 
than for claudin-5 (Fig. 2D). The claudin-5 specificity and the M01 effect 
on barrier permeability was further proved by permeability assays with 
MDCK-II cells. These were stably transfected with a flag-Cldn5 construct 
or with the empty vector alone. MDCK-II cells endogenously express 
claudins 1, 2, 3, 4, and 7 [15,33] and form a tissue barrier-like mono-
layer with typical transepithelial electrical resistance (TER) of ~100 Ω x 
cm [2,15]. M01 increased the permeability of the small dye Lucifer 
yellow (LY, 457 Da, Fig. 2E) in a concentration-dependent manner 
(MDCK-II-flag-Cldn5 control Papp: 0.875 ± 0.158 ⋅ 10− 5 cm/s; MDCK-II 
wildtype control Papp: 0.693 ± 0.188 ⋅ 10− 5 cm/s). It also decreased the 
TER (Fig. 2F) of flag-Cldn5 transfected MDCK-II, but not of cells 
expressing endogenous claudins alone. The treatment of MDCK-II-flag- 
Cldn5 cells with 50 μM M01 led to intracellular accumulation of 
claudin-5, whereas the solvent DMSO had no effect on the subcellular 
localisation (Fig. 2G). 
As claudin-5 deficient mice showed a BBB phenotype only [7], the 
main target of M01 should be the brain microvascular endothelium. 
Thus, the effect of M01 was confirmed in bEnd.3 cells, a cell culture 
model of the BBB. Among claudins, this cell line mainly expresses 
claudin-5 and, to a lower degree, claudin-12 (two orders of magnitude 
less mRNA), claudin-1 and claudin-3 (four orders less, see also Fig. 4A) 
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[6]. M01 interaction with claudin-5 led to a reduction of claudin-5 in 
bEnd.3 cells in both plasma membrane and cytosol (50% reduction in 
membrane, 43% in the cytosol) within 16 h after the addition of 50 μM 
M01 (Fig. 3A, B upper diagram). A slight but significant decrease of 
claudin-5 membranous and intracellular fluorescence intensity was 
observed for M01A (9% and 12%, respectively) and M01B (15% and 
32%, respectively). M01A and M01B represent the two molecular parts 
of M01, which have been studied to identify the active part of M01. For 
ZO-1, the junctional scaffolding protein, only a slight difference in their 
fluorescence was observed between treatments (Fig. 3A, B lower dia-
gram). However, M01 (Fig. 3C), but neither M01A nor B (Fig. 3D), 
affected the barrier properties of bEND.3 cells. The TER decreased 
immediately after administration of ≥7.5 μM M01. The maximum effect 
ion permeability was dependent on the concentration: 7.5 μM M01 
caused 18% reduction after 10 h, and 50 μM M01 caused 39% reduction 
after 23 h (Fig. 3C). Afterwards, the TER recovered slowly. 
The permeabilising effect of M01 in endothelial cells was accompa-
nied by claudin-5 decline after overnight treatment. M01 (50 μM) 
decreased the protein amount by 73% (Fig. 3E). Again, the protein 
amount of claudin-5 was not significantly reduced after 50 μM M01A 
treatment, but decreased after applying 50 μM M01B (by 41%). Incu-
bation of bEND.3 cells for 48 or 72 h with 20 μM M01 did not further 
decrease the claudin-5 protein amount, but washout of M01 after 17 h 
and cultivation for another 31 or 55 h in complete medium led to re-
covery of claudin-5 expression (Fig. 3F). The junctional localization of 
claudin-5 also recovered after M01 washout (Supplementary Fig. 2). The 
compounds M01, M01A and M01B were nontoxic for brain endothelial 
cells and for epithelial cells, at least up to 50 μM (Supplementary Fig. 3). 
We previously described the decrease of claudin-5 mRNA level of 
bEND.3 cells after claudin-5-peptide treatment [22]. Therefore, we 
examined the transcription of several TJ proteins after treatment of 
bEND.3 cells with 15 or 50 μM M01. The mRNA level of claudin-5 
decreased by about 81% after incubation with 50 μM M01 for 16 h. 
Transcription of other claudins and occludin was not significantly 
affected, but the level of ZO-1 mRNA declined by about 62% (Fig. 4A). 
The non-phosphorylated, active forms of the transcription factors 
β-catenin and FoxO1 (Fig.4B) establish a known claudin-5 repressor 
complex in endothelial cells. Under normal conditions, β-catenin is 
sequestered at adherens junctions with VE-cadherin. If the junctional 
complex is disturbed, the degradation of intracellular active β-catenin is 
inhibited, or higher β-catenin expression occurs, leading to intracellular 
accumulation of active β-catenin. FoxO1 and β-catenin shuttle to the 
nucleus, interact with each other and inhibit claudin-5 transcription 
(Fig. 4B) [34,37]. Consistent with this model, down-regulation of 
claudin-5 was paralleled by an increased amount of non-phosphorylated 
(S45) β-catenin in M01-treated endothelial cells as demonstrated by 
immunofluorescence staining (Fig. 4C). Quantification of the fluores-
cence intensity revealed higher signals in both cell membrane and 
cytosol (Fig. 4D). The cellular increase was confirmed by immunoblot-
ting, showing an elevated amount of non-phosphorylated (S45) β-cat-
enin after overnight treatment with M01 (Fig. 4E). In parallel to 
β-catenin, the phosphorylation level of FoxO1 at Thr24 was slightly 
reduced after M01 treatment (Fig. 4F). Other junctional proteins of the 
model were affected as well: VE-cadherin and the total protein amount 
of β-catenin slightly increased after 17 and 48 h M01 treatment and 
recovered after washout (Fig. 4G). As observed for the bEnd.3 immu-
nofluorescence stainings (Fig. 3A), ZO-1 was not reduced after 17 h M01 
incubation (Fig. 4G). However, the ZO-1 level decreased after 48 h of 
treatment with M01 and showed strongest reduction after washout of 
M01 (Fig. 4G). 
Next, we examined the efficacy of M01 in vivo. Because of the hy-
drophobic character of M01, the solubility in aqueous solution had to be 
increased for in vivo application. M01 is soluble in pure DMSO until 65 
mM. To reach at least the in vitro efficacious concentration of 50 μM, we 
had to inject 100 μl of 650 μM M01 dissolved in PBS i.v. (~1.3 ml blood 
volume per mouse) without increasing the final DMSO concentration 
above 1% or exceeding the maximum injectable volume (≤10% of blood 
volume). Therefore, HPβCD was utilized as an in vivo well tolerated 
solubility enhancer [38]. In a 20% HPβCD solution, 650 μM M01 dis-
solved finally (Supplementary Fig. 5; final concentration DMSO: 1%). 
The tolerability of M01, DMSO and/or HPβCD in mice was tested before 
further in vivo experiments. Mice received weekly injections for 4 weeks 
without showing any symptoms (e.g., weight loss, Supplementary 
Fig. 1). Pharmacokinetic experiments determined a half-life (t1/2z) for 
M01 in blood plasma of 18 min and for HPβCD of 66 min in mice 
(Supplementary Fig. 6). Besides M01 and HPβCD, nalidixic acid (M01A) 
was found as a metabolite in blood serum of mice after M01 injection 
with a maximal concentration (Cmax) of 2.2278 μM (517.3 ng/ml) after 
6 min and a t1/2z of 48 min. M01B was not detected. 
Based on the pharmacokinetic and toxicity experiments, the efficacy 
of M01 to permeabilise the BBB was investigated with an in vivo BBB 
sodium fluorescein permeability assay (Fig. 5A, top). Single injections of 
M01 in HPβCD did not increase the fluorescein amount in the brain 
tissue. Thus, we tested a variety of different injection patterns. Fig. 5A 
shows the data for the final triple i.v. injection procedure (18 h + 3 h +
3 h) of 2.9 μmol/kg M01 in 600 μmol/kg HPβCD into C57/BL6N mice. 
The maximum brain uptake of the small molecule Na-fluorescein (367 
Da) was found at a level of 1.5 ± 0.2 nmol/g tissue, 3 h after final in-
jection. The uptake was detectable up to 48 h (Fig. 5A, diagram on the 
left). However, after ~10 h no difference compared to the effect of 
HPβCD alone was observed. The mild permeability increase due to 
HPβCD alone was constantly detectable between 3 and 24 h. Liver tissue 
served as negative control and did not show changes in the uptake of 
fluorescein after M01 administration (Fig. 5A, diagram on the right). 
Mice bearing orthotopic glioblastoma xenografts (human U-87 MG 
cells) were investigated to provide evidence for improved drug delivery 
by M01 to the brain (Fig. 5B). Three hours after the final weekly M01 
administration, 28 μmol/kg (24 mg/kg) of the cytostatic drug paclitaxel 
(854 Da) were applied (40 μl/g b.w., i.v.), which was repeated weekly 
for four weeks. Paclitaxel had no effect on tumour growth when 
administered alone (Fig. 5B, upper brain section). However, when given 
in combination with M01, paclitaxel administration resulted in a 
Fig. 2. The effect of M01 on claudin-5 is highly specific, time and concentration dependent followed by internalization. A) As a measure for the M01 effect on 
claudin-5 (Cldn5), trans-interactions were calculated as fluorescence intensity enrichment in cell-cell contacts between HEK-293 cells transfected with Cldn5-YFP 
compared to the control. After treatment with M01 the Cldn5-YFP fluorescence recovered within 48 h. B) Column diagram of the calculated Cldn5-YFP enrich-
ment at cell-cell contacts in HEK-293 cells. The effect was time- and concentration dependent. The contact enrichment level of M01 treated HEK-293 cells returned to 
control values after 48 h (n ≥ 6 images). C) No effect of 20 μM M01 was observed on other BBB claudins in HEK-293 cells. Cells were transfected with YFP-Cldn1, 
YFP-Cldn3 and YFP-Cldn4 (green) and the cell membranes stained with trypan blue (red). D) Dissociation constants (Kd) of M01 and Cldns 1 to 5 determined by 
microscale thermophoresis (n ≥ 6 experiments). Data are shown as mean ± SEM. Two-tailed Mann-Whitney test compared to Cldn5, **, p < 0.005; ***, p ≤ 0.0003. 
E) Lucifer yellow (LY, 444 Da) permeability, and F) transcellular electrical resistance (TER) of MDCK-II (t0: ~80 Ω⋅cm2) and MDCK-II-flag-Cldn5 (t0: ~100 Ω⋅cm2) 
monolayer treated overnight with different concentrations of M01 (n ≥ 6 filter). LY permeability was normalised to the respective control values (untreated). The 
TER values after treatment were normalised with the values before treatment. G) Immunofluorescence staining of MDCK-II and MDCK-II-flag-Cldn5 cells after 
overnight incubation with M01. Claudin-5 (green) was visualised with a rabbit anti-Cldn5 antibody. For the junctional marker ZO-1 (red) mouse anti-ZO-1 was used. 
The arrows point at examples for internalised Cldn5 after M01 treatment. If not stated otherwise, Kruskal-Wallis-test followed by Dunn‘s multiple comparison-test 
was used. Mean ± SEM; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; significance related to DMSO control. Scale bar = 10 μm. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the web version of this article.) 
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significant reduction of the tumour size. The mean tumour size was only 
22% of the size of those mice, which received paclitaxel alone (Fig. 5B, 
lower section, diagram). 
To exclude the possibility of cytotoxicity by M01 or HPβCD for U-87 
MG cells, which might lead to decreased tumour growth, an in vitro 
cytotoxicity assay was performed. Even in combination, the cells were 
not affected by 0.5% DMSO, 1.5% HPβCD, and 50 μM M01 (in 0.5% 
DMSO). After 10 μM paclitaxel treatment the viability was decreased to 
55%, which was further reduced to 35% by combined treatment with 
HPβCD and M01 in DMSO (Fig. 5C). 
4. Discussion 
In general, the physio-chemical properties of M01 (table in Fig. 1A) 
satisfy the demands on oral bioavailability [9,23] and parenteral 
administration of a pharmaceutical product. Its molecular weight is in 
the range of 500 Da and the cLogP is 2.8. Such a cLogP is indicative of a 
suitable lipid- and water solubility and allows fair binding at 
Fig. 3. M01A and M01B are much less effective in decreasing endothelial tight junction functions than M01. A) Monolayer formed by murine brain endothelial 
(bEND.3) cells, a BBB tissue culture model, expressing endogenously claudin-5 (green) were treated with 50 μM M01, M01A (nalidixic acid) or B (3-phenyl-5- 
methoxyphenyl-1H-pyrazole) for 16 h. For immunofluorescence staining the antibodies mouse anti-Cldn5, rabbit anti-ZO-1, and DAPI for the nuclei were used. Scale 
bar = 20 μm. B) Quantification of the fluorescence intensity of claudin-5 (upper diagram) and ZO-1 (lower diagram) at the cell membrane and intracellular after 
treatment with M01, M01A or M01B compared to DMSO treated bEND.3 cells. Mean ± SEM, n > 200 cells. Kruskal-Wallis-test followed by Dunn‘s multiple 
comparison-test. Mean ± SEM; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. C) and D) impedance was determined by electric cell-substrate impedance sensing (ECIS) at 
4000 Hz. Values were shown as normalised to impedance values before treatment with different concentrations of M01 (C) or 50 μM M01A and M01B (D). The arrow 
indicates the beginning of the treatment of the bEnd.3 monolayer. Mean ± SEM, n ≥ 4 experiments. E) M01 and slightly M01B reduced the protein expression of 
claudin-5, immunoblot quantification corrected by GAPDH values. Mean ± SEM, n = 7 immunoblots. One-way-ANOVA and Dunnett’s multiple comparison test; *, p 
≤ 0.05 and ***, p ≤ 0.001 vs. DMSO. F) Immunoblot of bEND.3 cells treated for 17, 48 and 72 h with M01 and recovery after 17 h M01, M01 washout and culture 
medium for 31 h and 55 h (n = 3 blots). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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intramembranous and soluble parts of transmembrane proteins, such as 
claudin-5, which was targeted in this study. The number of HB-acceptors 
and -donators as well as the number of rotating bonds is in the required 
range (≤10, ≤5 and ≤ 10, respectively [9,23]), thus providing flexibility 
necessary to adapt to the highly dynamic function of claudin-5 within 
the TJs [24]. This coincides with our docking studies. The resulting 
interaction model shows a preferred association of M01 to the extra-
cellular domain and an adhering outward-directed transmembrane 
patch of the claudin (Fig. 6). 
Compounds envisioned to improve drug delivery through pharma-
cological barriers - termed drug enhancers - are required to exhibit a 
high affinity to a tissue-specific target and a transient and moderate 
barrier permeabilisation. M01 meets these requirements at the BBB. It 
associates with claudin-5, whose knockout causes a specific BBB 
phenotype [7], and it acts in a low micromolar range. Dissociation 
constants found for other barrier-forming claudins are at least 3.93 times 
Fig. 4. M01 is inhibiting claudin-5 expres-
sion in brain endothelial cells, at protein and 
mRNA level. A) mRNA expression of junc-
tional proteins in bEnd.3 cells detected by 
qRT-PCR (ΔCT, cycle threshold normalised 
to β-actin), 16 h incubation, M01 in 0.5% 
DMSO. Mean ± SEM, n = 6 experiments. ZO- 
1, Zonula occludens protein 1; VE-cadherin, 
vascular endothelial cadherin. B) Sketch of 
claudin-5 expression inhibition by the active, 
non-phosphorylated form of β-catenin and 
forkhead box protein O1 (FoxO1). 1. Under 
normal, barrier-forming conditions, β-cat-
enin accumulates at the cell membrane 
bound to the adherens junctional complex. 2. 
Intercellular β-catenin is phosphorylated and 
subsequently degraded. 3. Inhibition of the 
β-catenin destruction complex leads to 
accumulation of intracellular β-catenin, 
which shuttles into the nucleus. 4. Together 
with FoxO1, β-catenin functions as a claudin- 
5 transcription inhibitor binding to the Wnt 
response element (WRE) in the promotor 
region [34–36]. C) Immunofluorescence 
staining of bEnd.3 cells 16 h after incubation 
with 15 and 50 μM M01. S45 non- 
phosphorylated “active” β-catenin (rabbit, 
green) is known to be able to shuttle into the 
nuclei (blue, DAPI) and acts as a repressor of 
Cldn5 transcription [34]. M01 intensified the 
membrane and intracellular localisation of 
S45 non-phosphorylated β-catenin. Scale 
bar, 10 μm. D) Quantification of cellular 
distribution, mean ± SEM, n ≥ 21 images. E) 
and F) immunoblot and quantification of E) 
non-phospho (S45) β-catenin (β-cat, 92 kDa) 
and F) phospho (T24) FoxO1 (72–85 and 95 
kDa) normalised to GAPDH (36 kDa). Mean 
± SEM, n = 6 blots. One-way-ANOVA and 
Dunnett’s multiple comparison test. *, p ≤
0.001. G) Immunoblots of ZO-1, VE-cad-
herin, non-phospho (S45) β-catenin and 
β-catenin after M01 treatment and recovery 
for 31 h in culture medium, n ≥ 3 immuno-
blots. If not stated otherwise Kruskal-Wallis- 
test followed by Dunn‘s multiple 
comparison-test was used. *, p ≤ 0.05; **, p 
≤ 0.01; ***, p ≤ 0.001. (For interpretation of 
the references to colour in this figure legend, 
the reader is referred to the web version of 
this article.)   
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lower, and their individual expression at the BBB is less than 1% of 
claudin-5 [6]. In addition, if claudin-5 is additionally expressed, M01 
specifically enhances the permeability of a small molecular weight 
marker (LY) through MDCK-II, a TJ- and barrier-forming cell layer [21]. 
In mouse experiments, the permeability of fluorescein through the BBB 
is four times enhanced, peaks after three hours and returns to the level of 
HPβCD permeability within 6 to 12 h. It should be mentioned that the 
maximum uptake of 1.5 ± 0.2 nmol fluorescein per g brain tissue de-
pends on the detection method we used, application of other methods 
might yield different results. A smaller, longer lasting permeability in-
crease might be caused by HPβCD. Cyclodextrins can remove cholesterol 
from cell membranes and thus, the permeability of barrier forming cell 
Fig. 5. M01 transiently permeabilises the blood-brain barrier for small molecules in vivo and enables paclitaxel to inhibit brain tumour growth. (A) Permeabilisation 
of the murine blood-brain barrier by M01 as determined by cerebral fluorescein uptake. 2.9 μmol/kg M01 in 600 μmol/kg HPβCD (2-hydroxypropyl-β-cyclodextrin), 
600 μmol/kg HPβCD or PBS+/+ (phosphate buffered solution with Ca2+/Mg2+) were administered three times into the tail vein at 0, 18 and 21 h. 242 μmol/kg Na- 
fluorescein (367 Da) was injected into the tail vein at different time points after the last M01 treatment. Mean ± SEM, n = 3–15 mice. (B) For the experimental 
treatment of an orthotopic glioma model, human U-87 MG cells were administered intrathecally into immunodeficient NMRI-Foxn1 nu− /− mice. After five days, mice 
were treated once a week (i.v.) for four weeks with 28 μmol/kg paclitaxel alone or paclitaxel together with M01 in HPβCD (administration pattern: 0/18/21 h M01 
and 3 h later paclitaxel). Left: cresyl violet staining of 10 μm cryogenic brain sections. Tumour tissue stained in dark violet. Mean ± SEM, n = 6–8 mice. C) Viability 
(MTT) assay to prove sensitivity of U-87 MG cells to paclitaxel and M01. Cell Monolayer were treated with 0.5% DMSO, 1.5% HPβCD, 50 μM M01, 10 μM paclitaxel 
or in combinations. Values were calculated in comparison to untreated cells in percent. A, B and C: Kruskal-Wallis-test with Dunn’s multiple comparison test; *, p ≤
0.05; **, p ≤ 0.01; ***, p ≤ 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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monolayer is increasing [39,40]. Taken together, these results suggest 
that M01, perhaps in synergy with HPβCD, permeabilises the BBB 
preferentially via claudin-5, moderately and for a short time. The 
strength and duration of the effect has the potential to facilitate drug 
permeation through the BBB. 
The short-term action of M01 is due to fast retention, metabolisation 
and degradation (Supplementary Fig. 6). Only traces of M01 and its 
nalidixic acid part, but not the 3-phenyl-5-methoxyphenyl-1H-pyrazole 
part of M01 are detectable in urine and faeces. Tolerance studies with 
weekly administration over four weeks did not affect behaviour, growth, 
or appearance of the treated mice. M01 and possible metabolites seemed 
to be well tolerated in mice. These results also support the assumption, 
that a low-grade and partial permeabilisation of the BBB is non- 
hazardous. Similar tolerability is observed after short-term per-
meabilisation of the BBB by a claudin-5 peptidomimetic [22]. 
The high and mostly specific M01 affinity to claudin-5 accounts for 
its mode of action. Initially, the M01 binding at the extracellular domain 
partially suspends the trans-interaction. This disturbs the TJ structure, 
which, in turn, temporarily reduces the intercellular tightness for small- 
sized drugs, such as cytostatics. A similar effect is assumed after 
administration of mannitol, a drug enhancer applied in lymphoma 
therapy [41]. This drastic and unspecific procedure breaches the BBB by 
osmotic shrinkage of the endothelium, thus completely opening TJs 
between cells [42]. It bears a high risk of side effects by uptake of larger 
molecules and cells into the brain. Moreover, a low efficacy has been 
reported for a considerable number of patients [43]. If mannitol fails to 
render the BBB permeable, chemotherapeutic drugs do not reach the 
tumour behind the intact barrier, and the disease will progress [41]. 
Besides mannitol, other unspecific techniques with harmful side actions 
have been developed for TJ modulation at the BBB. Highly intensive and 
focused ultrasound increases delivery of chemotherapeutic drugs in a 
glioblastoma model [44] after complete BBB breakdown [45]. Vascular 
endothelial growth factor administration results, among other effects, in 
downregulation of claudin-5 and impairment of TJs, as shown for de-
livery of doxorubicin-loaded nanoparticles [46]. But it also opens the 
BBB for large molecules and causes unspecific alterations in peripheral 
organs [47]. Nontoxic targeting of claudin-5 has been suggested via 
siRNA [48], shRNA [49] or monoclonal antibodies [50]. Compared to 
the acute action of M01, these approaches show a more persistent per-
meabilisation of the BBB. 
Delayed in time, M01 permeabilises the BBB by reduction of the 
claudin-5 protein level at the TJs. In this regard, we assume claudin-5 
internalization and degradation after incubation with M01. The same 
effect was observed for a claudin-5 peptidomimetic [22]. This peptide is 
co-internalised with the cell surface localised claudin-5 leading to 
reduced claudin-5 protein amount. Surprisingly, the peptide and M01 
Fig. 6. 3D-interaction model between M01 (blue) 
and extracellular loop (ECL) domain with adjoining 
transmembrane domains (TMs) of murine claudin-5. 
The proposed binding area predominantly consists 
of a β-sheet including five β-strands (four from ECL1, 
one from ECL2) flanked by an α-helix (from ECL2); 
red amino acids: distance to M01 ≤ 4.5 Å. A) Amino 
acid sequence of claudin-5 ECLs and neighbourhood: 
(*), in Mammalia conserved claudin-5 residues; (:), 
strongly similar; (.), weakly similar; red, residues in 
binding distance (≤4.5 Å). B) Interaction model be-
tween M01 and claudin-5 (ribbon model) as ener-
getically favourable conformation (SwissDock, [30]), 
with particular consideration of aromatic interaction 
sites (W47 right inset, W51 left inset). Structural 
prediction of claudin-5 [31] adapted from crystal 
structure of claudin-15 [13]. Dashed lines, predicted 
extracellular membrane surfaces. (For interpretation 
of the references to colour in this figure legend, the 
reader is referred to the web version of this article.)   
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also affect the claudin-5-transcription (Fig. 4A). The transcription fac-
tors β-catenin and FoxO1 are known to regulate claudin-5 in endothelial 
cells if β-catenin is not sequestered at adherens junctions and its phos-
phorylation and degradation is inhibited (Fig. 4B) [34,37,50]. In our 
experiments, VE-cadherin and β-catenin remained at the cell membrane 
during M01 treatment and their protein amounts increased (Fig. 4A, G). 
However, we also found increased amounts of non-phospho (S45) 
β-catenin and a slightly (but not significantly) reduced level of T24- 
phospho FoxO1 [35,36]. Phosphorylation of FoxO1 by the kinase Akt 
at T24 leads to nuclear export of FoxO1 [51,52]. Our results support the 
assumption of M01-induced inhibition of claudin-5 transcription by non- 
phospho FoxO1 and β-catenin. The reason for increased amounts of 
active β-catenin and FoxO1 needs further investigations. 
For the purpose of a potential modulation of the drug enhancer ef-
fect, it is particularly interesting to identify a certain M01 moiety, 
responsible for BBB permeabilisation and loss of claudin-5. The results 
indicate that the entire structure is essential for maximum activity. Both 
the 3-phenyl-5-methoxyphenyl-1H-pyrazole and nalidixic part alone are 
much less effective. Both parts contain at least one aromatic ring, which 
is assumed to support interaction between claudin-5 and M01. However, 
the part with the 3-phenyl-5-methoxyphenyl-1H-pyrazole, which has a 
larger surface area and higher flexibility, shows more interaction sites 
towards claudin-5 in the docking model of M01 in comparison to the 
nalidixic acid part (Fig. 6). 
M01 permeabilises the BBB transiently and moderately for small 
molecules. The drug enhancement activity is verified by application of 
the cytostatic drug paclitaxel (molecular weight, 854 Da). As reported 
earlier [53], paclitaxel does not exhibit cytostatic activity for brain tu-
mours. However, it significantly reduces the glioblastoma growth after 
M01 pre-treatment in an orthotopic xenograft model. Nevertheless, 
some questions remain, e.g., if the increase of vascular permeability for 
cytostatic drugs in the non-tumour brain regions induces toxicity on 
cells of the central nervous system as reported for paclitaxel on astro-
cytes [54]. Thus, further investigations are necessary to prove the 
applicability of M01 in brain tumour therapy. 
In conclusion, M01 is identified as the first small molecule specif-
ically modulating claudin-5 and permeabilising the BBB for drug-like 
molecules. The use of M01 for drug delivery through the BBB demon-
strates that a targeted approach has a strong potential to improve the 
chemotherapeutic effectiveness for primary brain tumours and cerebral 
metastases. Moreover, this concept is not restricted to treatment of 
neoplasms and should be tested for the pharmacotherapy of other ce-
rebral diseases, such as Alzheimer’s disease, epilepsy, or stroke. 
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